Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Understanding PIEZO2 mutations and sensory disorders

9

Mar 2026

Understanding PIEZO2 mutations and sensory disorders

Every time we feel a gentle tap on the skin, specialized nerve cells convert that physical force into an electrical signal that the brain can interpret as touch. While scientists have long known that a protein called PIEZO2 acts as a key sensor for touch, it remained unclear why PIEZO2 is specialized for the localized mechanical forces experienced by sensory neurons, whereas its close relative PIEZO1 responds to broader mechanical stresses such as those generated when cells stretch, as occurs in blood vessels.

Redefining the "aging brain" through diverse data

9

Mar 2026

Redefining the "aging brain" through diverse data

Age is more than just one number. While neuroscientists used to think of cognitive aging as a single trendline, they now realize that vast individual differences require a more predictive and personalized approach. As they uncover more factors that affect cognition over time, they are realizing that modeling the aging brain requires more diverse data than traditionally captured.

Targeting Wnt signaling to solve the dental pulp challenge

9

Mar 2026

Targeting Wnt signaling to solve the dental pulp challenge

Dental pulp regeneration remains a major clinical challenge. Researchers have discovered that SMAD7 directly forms a transcriptional complex with β-catenin in human dental pulp stem cells, activating Wnt signaling and promoting regenerative gene expression.

Navigating the structural challenges of AI in radiology

9

Mar 2026

Navigating the structural challenges of AI in radiology

Artificial intelligence (AI) has the potential to redefine how radiology is practiced, as well as highlight specific challenges for radiology departments, according to new research from the Journal of the American College of Radiology (JACR).

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.